Neuromodulation of the Peroneal Nerve Safe for Overactive Bladder
(MedPage Today) -- Electrical transcutaneous neuromodulation (eTNM) of the peroneal nerve led to fewer side effects compared with solifenacin (Vesicare) in the treatment of overactive bladder, a randomized trial showed.
Among 76 treatment-naive... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - March 25, 2023 Category: OBGYN Source Type: news
VESIcare LS (Solifenacin Succinate Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 24, 2022 Category: Drugs & Pharmacology Source Type: news
Zydus Cadila gets USFDA nod for overactive bladder treatment drug
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Solifenacin Succinate tablets, in the strengths of 5 mg and 10 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 20, 2020 Category: Pharmaceuticals Source Type: news
VESIcare LS (Solifenacin Succinate Oral Solution) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 4, 2020 Category: Drugs & Pharmacology Source Type: news
VESIcare LS Approved for Neurogenic Detrusor Overactivity
WEDNESDAY, May 27, 2020 -- VESIcare LS (solifenacin succinate) oral suspension is now approved to treat neurogenic detrusor overactivity (NDO) in children 2 years and older, the U.S. Food and Drug Administration announced Tuesday.
VESIcare... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 27, 2020 Category: General Medicine Source Type: news
FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients
NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has approved VESIcare LS (solifenacin succinate)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 27, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Pediatric Patients
NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has approved VESIcare LS (solifenacin succinate)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 27, 2020 Category: Drugs & Pharmacology Source Type: news
Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladder
The approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2019 Category: Pharmaceuticals Source Type: news
Alembic Pharma gets USFDA nod for overactive bladder treatment drug
The company has received approval from the USFDA for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 20, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Mirabegron, Solifenacin Combo for OAB FDA Approves Mirabegron, Solifenacin Combo for OAB
The FDA has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate for the treatment of overactive bladder (OAB).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 9, 2018 Category: Consumer Health News Tags: Urology News Alert Source Type: news
FDA Approves Supplemental New Drug Application for Myrbetriq (mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 7, 2018 Category: Drugs & Pharmacology Source Type: news
Zydus Cadila gets USFDA nod for two drugs
The group has also received the tentative approval for Solifenacin Succinate tablets in strengths of 5 mg and 10 mg, Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 15, 2017 Category: Pharmaceuticals Source Type: news
Glenmark Pharma's overactive bladder drug gets USFDA nod
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 22, 2017 Category: Pharmaceuticals Source Type: news
SMC backs drug for male urinary symptoms in Scotland
The Scottish Medicines Consortium has approved solifenacin 6mg/tamsulosin 0.4mg (Vesomni) for use in NHS Scotland. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - March 24, 2014 Category: Nursing Source Type: news
FDA OK’s First OTC Remedy For Overactive Bladder
WebMD Medical News
By Kathleen Doheny
Reviewed by Laura J. Martin, MD
Jan. 25, 2013 — The FDA has approved Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women 18 and older.
The condition affects more than 20 million American women, according to Merck, the drug’s manufacturer.
It will still only be available in prescription form for men.
Oxytrol helps relax the overactive bladder muscle that leads to symptoms such as the sudden need to urinate and leaking of urine.
Oxytrol for Women is in the form of a patch, applied to the skin every four days, Merck says.
It is expected to ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 30, 2013 Category: Consumer Health News Authors: mreal197 Tags: WebMD News Source Type: news
